Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914600 · ClinicalTrials.gov registry record · Phase 3
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
A Phase 3 study, sponsored by Lakefront Biotherapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,188
- Enrollment target
NCT02914600: Clinical Trial Phase 3 study, sponsored by Lakefront Biotherapeutics.
NCT02914600 is a Phase 3 study that was terminated before completion, run by Lakefront Biotherapeutics. The registered enrollment target is 1,188 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914600, a Phase 3 study, was terminated before completion, sponsored by Lakefront Biotherapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,188 participants
- Enrollment target
Study Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Interventions
- DRUG Placebo
- DRUG Filgotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,188 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2023-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914600
The ClinicalTrials.gov registry entry for NCT02914600 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02914600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02914600 about?
NCT02914600 is a clinical study titled "Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease". The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
What is the current status of trial NCT02914600?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,188 participants. The study started on 2017-03-17. Estimated completion is 2023-08-01.
What interventions are being tested in trial NCT02914600?
The interventions under investigation include: Placebo (DRUG), Filgotinib (DRUG).
Who is sponsoring clinical trial NCT02914600?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.